Abivax SA Sponsored ADR (NASDAQ:ABVX) Given Consensus Rating of “Moderate Buy” by Analysts

Abivax SA Sponsored ADR (NASDAQ:ABVX) has earned a consensus recommendation of “Moderate Buy” from the sixteen analysts that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and fourteen have issued a buy rating on the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $148.5385.

Several research firms have recently commented on ABVX. Wall Street Zen raised shares of Abivax from a “sell” rating to a “hold” rating in a research report on Saturday, May 23rd. Oddo Bhf reaffirmed an “outperform” rating on shares of Abivax in a research report on Thursday, April 9th. Citigroup reissued an “outperform” rating on shares of Abivax in a research report on Tuesday, June 2nd. Wedbush raised their target price on Abivax from $90.00 to $110.00 and gave the company a “neutral” rating in a research note on Tuesday, June 30th. Finally, Citizens Jmp restated a “market outperform” rating and set a $187.00 price target on shares of Abivax in a research report on Wednesday, July 1st.

Institutional Trading of Abivax

A number of institutional investors and hedge funds have recently bought and sold shares of the company. FNY Investment Advisers LLC increased its holdings in shares of Abivax by 7.3% in the 2nd quarter. FNY Investment Advisers LLC now owns 7,605 shares of the company’s stock worth $1,013,000 after purchasing an additional 519 shares in the last quarter. Versant Capital Management Inc bought a new position in shares of Abivax during the second quarter valued at $30,000. Militia Capital Management LLC bought a new position in shares of Abivax during the first quarter valued at $1,893,000. Seven Fleet Capital Management LP boosted its position in shares of Abivax by 218.9% during the first quarter. Seven Fleet Capital Management LP now owns 43,052 shares of the company’s stock valued at $4,794,000 after buying an additional 29,553 shares during the last quarter. Finally, Optiver Holding B.V. boosted its position in shares of Abivax by 985.6% during the first quarter. Optiver Holding B.V. now owns 4,538 shares of the company’s stock valued at $505,000 after buying an additional 4,120 shares during the last quarter. 47.91% of the stock is currently owned by institutional investors.

Abivax Stock Performance

Shares of ABVX stock opened at $134.91 on Wednesday. The company has a market capitalization of $10.76 billion, a P/E ratio of -25.89 and a beta of 0.87. Abivax has a fifty-two week low of $8.85 and a fifty-two week high of $148.83. The stock has a 50 day moving average price of $116.22 and a two-hundred day moving average price of $118.45.

Abivax (NASDAQ:ABVX) last released its quarterly earnings data on Friday, May 22nd. The company reported ($0.71) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.94) by $0.23. The firm had revenue of $1.56 million during the quarter, compared to analysts’ expectations of $0.40 million. As a group, equities analysts predict that Abivax will post -3.4 earnings per share for the current year.

About Abivax

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.